RESEARCH ARTICLE

Male Circumcision and STI Acquisition in Britain: Evidence from a National Probability Sample Survey

Virginia Homfray¹, Clare Tanton¹, Robert F. Miller¹, Simon Beddows², Nigel Field¹, Pam Sonnenberg¹, Kaye Wellings³, Kavita Panwar², Anne M. Johnson¹, Catherine H. Mercer¹*

¹ Research Department of Infection and Population Health, University College London, London, United Kingdom, ² Virus Reference Department, Public Health England, London, United Kingdom, ³ Centre for Sexual and Reproductive Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom

* c.mercer@ucl.ac.uk

Abstract

Background

It is well-established that male circumcision reduces acquisition of HIV, herpes simplex virus 2, chancroid, and syphilis. However, the effect on the acquisition of non-ulcerative sexually transmitted infections (STIs) remains unclear. We examined the relationship between circumcision and biological measures of three STIs: human papillomavirus (HPV), Chlamydia trachomatis and Mycoplasma genitalium.

Methods

A probability sample survey of 15,162 men and women aged 16-74 years (including 4,060 men aged 16-44 years) was carried out in Britain between 2010 and 2012. Participants completed a computer-assisted personal interview, including a computer-assisted self-interview, which asked about experience of STI diagnoses, and circumcision. Additionally, 1,850 urine samples from sexually-experienced men aged 16-44 years were collected and tested for STIs. Multivariable logistic regression was used to calculate adjusted odds ratios (AOR) to quantify associations between circumcision and biological measures of three STIs: human papillomavirus (HPV), Chlamydia trachomatis and Mycoplasma genitalium.

Results

The prevalence of circumcision in sexually-experienced men aged 16-44 years was 17.4% (95%CI 16.0-19.0). There was no association between circumcision and biological measures of three STIs: human papillomavirus (HPV), Chlamydia trachomatis and Mycoplasma genitalium.
Conclusions

Circumcised men had reduced odds of HPV detection in urine. These findings have implications for improving the precision of models of STI transmission in populations with different circumcision prevalence and in designing interventions to reduce STI acquisition.

Introduction

It is well-established that male circumcision reduces HIV acquisition.[1–3] A meta-analysis concluded that male circumcision is also associated with a lower risk of infection with herpes simplex virus type 2, chancroid and syphilis.[4] However, the effect of male circumcision on non-ulcerative sexually transmitted infections (STIs) remains unclear.

Human Papillomavirus (HPV) is highly prevalent.[5] Persistent infection with 'high-risk' types (HR-HPV) is essential for the development of cervical cancer in women, and anal cancer in both men and women. HR-HPV has also been associated with penile cancers in men.[6] 'Possible HR-HPV' types are those with no clear evidence of carcinogenicity in humans, and types HPV-6 and HPV-11 are responsible for around 85% of genital warts.[7] A meta-analysis using detection of HPV DNA and/or genital warts (by self-report/clinical examination) as outcomes found that circumcision was strongly protective against HPV DNA detection (summary odds ratio (OR) 0.57; 95% Confidence Interval (CI) 0.45–0.71), but with substantial between-study heterogeneity, which may partly reflect the fact that most of the data were from convenience samples with relatively small sample sizes, while circumcision did not afford protection against genital warts.[8]

Chlamydia trachomatis and Mycoplasma genitalium are bacterial STIs possibly associated with upper reproductive tract infection in women. A randomised trial of circumcision to prevent acquisition of HIV in Kenya found Chlamydia infection was reduced in the intervention arm, but this lacked significance (incidence rate ratio 0.87, 95% CI 0.65–1.16).[9] However, in the same trial, circumcision almost halved the odds of detecting M. genitalium (OR 0.54; 95% CI 0.29–0.99) after controlling for behavioural risks.[9] A similar trial in South Africa demonstrated a decrease in prevalence of C. trachomatis in circumcised participants (adjusted OR 0.56; 95% CI 0.32–1.00).[10] However, few other studies have investigated the association between circumcision and these pathogens.

Our study examined the relationship between male circumcision and reporting previous STI diagnoses or detecting HPV, C. trachomatis and M. genitalium in urine among men in the British general population.

Materials and Methods

The third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) was a stratified probability sample survey of 15,162 men and women (6293 men) aged 16–74 years in Britain, who were interviewed during 2010–2012. The overall response rate was 57.7%. Participants were interviewed using computer-assisted face-to-face and self-interviews (CASI). The CASI included questions about male circumcision, sexual behaviour and history of STI diagnoses. Further methodological details have been described elsewhere.[11,12]

After the interview, a sample of participants aged 16–44 years who reported at least one lifetime sexual partner were invited to provide urine for STI testing.[5,11] Samples were tested for HPV, C. trachomatis and M. genitalium. STI test results were available from 1,850 men. HPV...
types were classified as high-risk, possible high-risk or HPV-6/11 using the IARC Monograph Working Group classification [13] (see Table 2). Details of the urine collection methods and testing procedures are published elsewhere.[5] Briefly, detection of *C. trachomatis* used the Aptima Combo 2 assay (Hologic Gen-Probe) as the initial screen and all positive or equivocal results were confirmed with the Aptima monospecific assay. An in-house Luminex-based genotyping assay was used to detect HPV types.[14] *M. genitalium* detection used an in-house Real-Time PCR assay which targets the adhesin protein (MgPa) gene, [15] with positive or equivocal results confirmed using a Genprobe Mycoplasma test. [16]

Stata (version 12.1) was used for all statistical analyses accounting for the stratification, clustering, and weighting of the sample, which was broadly representative of the British population.[11] Analyses were additionally weighted for unequal urine selection probabilities and differential urine sample response.[11] The denominator was limited to men aged 16–44 years reporting one or more lifetime partner. Prevalence estimates of self-reported circumcision with 95% confidence intervals (CIs) are presented. Associations between circumcision and demographic and behavioural variables were examined using logistic regression to calculate odds ratios (ORs). Crude and age-adjusted ORs are presented. To examine the association between circumcision and self-reported STI diagnoses or biological outcomes multivariable analysis was used to calculate ORs adjusted for age, ethnicity, same-sex experience and either number of lifetime partners (for STI diagnosis outcomes) or number of partners without a condom in the past year (for biological outcomes) (adjusted OR [AOR]).

All participants were given an information leaflet to read prior to participating in the survey and had the opportunity to discuss this with the interviewer. Verbal informed consent was obtained for participation in the interview and interviewers had to confirm that respondents had read the information leaflet in the computer programme before commencing the interview. Participants gave written informed consent for anonymised testing of urine samples, without the return of results, the ethical rationale for which has been previously described.[14] The Natsal-3 study, including the consent procedures, was approved by the Oxfordshire Research Ethics Committee A (reference: 09/H0604/27). All participants provided their own consent to participate, however for 16–17 year olds living at home, a parent/guardian provided additional verbal assent for participation. At the time of writing, the Natsal-3 data are being prepared for archiving with the UK Data Archive in June 2015, but before then, researchers may contact the Natsal-3 team to seek advance access to the corresponding data, and are directed to the Natsal website for further information (www.natsal.ac.uk).

**Results**

The prevalence of reported circumcision in sexually-experienced men aged 16–44 resident in Britain was 17.4% (95% CI 16.0–19.0). Prevalence increased with age, from 13.2% (95% CI 11.3–15.5) among men aged 16–24 to 18.4% (95% CI 15.5–21.6) among men aged 35–44 (Table 1). Prevalence of male circumcision varied greatly according to ethnicity and religion, with men from ethnic minority backgrounds being significantly more likely to report being circumcised than men of White ethnicity. In unadjusted analyses, the odds of circumcision were 45.01 (95%CI 24.26–83.51) times higher in Muslim men than in those of no religious background. This association remained after adjusting for age. There were no associations between circumcision and the key sexual behaviours studied.

Circumcision was not associated with reporting previous diagnosis/es of any STI, or specifically chlamydia or genital warts in 16–44 year old men (Table 2). Results were similar in 16–74 year old men (data not shown). In unadjusted analyses, any HPV type was less likely to be detected in circumcised men as were HR-HPV and possible HR-HPV types (but not HPV
Table 1. Variations in the prevalence of circumcision by key sociodemographic factors and sexual behaviours reported by sexually–experienced men aged 16–44 years in Britain’s third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

| Sociodemographics | Circumcised % (95%CI) | OR (95%CI) | p-value | Age-adjusted OR (95%CI) | Denom. (unwt, wt) | p-value |
|--------------------|------------------------|------------|---------|--------------------------|------------------|---------|
| **All**            |                        |            |         |                          |                  |         |
| **Age (years)**    |                        |            |         |                          |                  |         |
| 16–24              | 13.20% (11.3–15.5)     | 1          | -       |                          | 1343, 979        | 0.0005  |
| 25–34              | 19.60% (17.5–22.0)     | 1.6        | (1.26–2.03) |                          | 1425, 1273       |         |
| 35–44              | 18.40% (15.5–21.6)     | 1.47       | (1.12–1.94) |                          | 777, 1374        |         |
| **Relationship status** |                        |            |         |                          |                  |         |
| Living with partner | 19.10% (17.0–21.5)     | 1          | -       |                          | 1603, 2130       | 0.0324  |
| Steady relationship, not cohabiting | 13.80% (11.0–17.2) | 0.68 | (0.50–0.91) | 0.75 | (0.54–1.05) | 769, 586 |
| No steady relationship, previously cohabited | 15.60% (12.8–18.7) | 0.78 | (0.59–1.02) | 0.88 | (0.64–1.21) | 821, 627 |
| No steady relationship, never cohabited | 15.50% (12.8–18.7) | 0.78 | (0.59–1.02) | 0.88 | (0.64–1.21) | 821, 627 |
| **Academic qualifications** |                        |            |         |                          |                  |         |
| No academic qualifications | 16.60% (12.0–22.6) | 1          | -       |                          | 316, 347         | 0.0012  |
| Academic qualifications typically gained at age 16 | 13.60% (11.5–16.1) | 0.79 | (0.51–1.21) | 0.81 | (0.53–1.25) | 1216, 1248 |
| Studying for/attained further academic qualifications | 19.80% (17.7–22.1) | 1.24 | (0.83–1.86) | 1.35 | (0.90–2.04) | 1815, 1860 |
| **Ethnic group**   |                        |            |         |                          |                  |         |
| White              | 12.00% (10.8–13.4)     | 1          | -       |                          | 3106, 3093       | <0.0001 |
| Mixed              | 37.40% (26.1–50.3)     | 4.38       | (2.58–7.45) | 4.63 | (2.72–7.88) | 88, 82  |
| Asian/Asian British | 48.80% (40.0–57.6)     | 6.97       | (4.80–10.13) | 6.83 | (4.67–9.97) | 175, 254 |
| Black/Black British | 64.40% (53.9–73.8)     | 13.26      | (8.38–20.99) | 13.27 | (8.37–21.02) | 123, 137 |
| Other              | 29.80% (17.0–46.8)     | 3.10       | (1.50–6.43) | 3.15 | (1.50–6.64) | 47, 53  |
| **Religion**       |                        |            |         |                          |                  | <0.0001 |
| None               | 13.60% (12.0–15.4)     | 1          | -       |                          | 2288, 2249       | <0.0001 |
| Christian          | 16.20% (13.6–19.3)     | 1.23       | (0.96–1.58) | 1.2 | (0.93–1.55) | 1022, 1091 |
| Muslim             | 87.60% (79.5–92.8)     | 45.01      | (24.26–83.51) | 45.44 | (24.62–83.86) | 119, 149 |
| Hindu              | 3.90% (1.2–11.7)       | 0.26       | (0.08–0.83) | 0.24 | (0.07–0.79) | 45, 69  |
| Other              | 21.50% (13.3–32.9)     | 1.74       | (0.96–3.16) | 1.8 | (0.98–3.27) | 66, 63  |
| **Sexual behaviours** |                        |            |         |                          |                  |         |
| Number of sexual partners over the lifetime |                        |            |         |                          |                  | 0.256   |

(Continued)
types 6 and 11; Table 2). Circumcised men were also less likely to have *C. trachomatis*, but not *M. genitalium* detected (Table 2). After adjusting for key demographic and behavioural variables (Table 2), circumcised men were still less likely to have any HPV-type detected in their urine when compared with uncircumcised men (AOR 0.26, 95% CI 0.13–0.50). An association also remained for both HR-HPV (AOR 0.14, 95% CI 0.05–0.40) and possible HR-HPV (AOR 0.24, 95% CI 0.06–0.94) and for *C. trachomatis* (AOR 0.09, 95% CI 0.01–0.77). Unadjusted and adjusted ORs for the association between circumcision and *M. genitalium* differed substantially due to confounding by ethnicity.

### Table 1. (Continued)

| Circumcised % (95%CI) | OR (95%CI) | p-value | Age-adjusted OR (95%CI) | Denom. (unwt, wt)† |
|-----------------------|------------|---------|-------------------------|---------------------|
| 1 21.00% (16.8–25.9)  | 1          | -       | 1                       | 483, 490            |
| 2 20.50% (15.1–27.0)  | 0.97       | (0.62–1.33) | 0.99                  | (0.63–1.56)          |
| 3–4 17.40% (13.9–21.6) | 0.8        | (0.55–1.15) | 0.79                  | (0.55–1.14)          |
| 5–9 16.00% (13.1–19.2) | 0.72       | (0.50–1.02) | 0.68                  | (0.48–0.97)          |
| 10+ 16.40% (14.3–18.7) | 0.74       | (0.53–1.02) | 0.69                  | (0.49–0.96)          |

**Same sex experience, ever**

| p-value | p-value |
|---------|---------|
| 0.8434  | 0.8289  |

**Number of sexual partners, past year**

| p-value | p-value |
|---------|---------|
| 0.723   | 0.7831  |

**Number of sexual partners without a condom, past year**

| p-value | p-value |
|---------|---------|
| 0.6247  | 0.9503  |

1 Unweighted, weighted denominators: all 16–44 year old men reporting at least one lifetime partner by the time of their interview for Natsal-3
2 Participants aged ≥17 years
3 Includes both opposite and same-sex partners
4 Same-sex experience involving genital contact

doi:10.1371/journal.pone.0130396.t001
Discussion

Findings from this large British population-based survey show that male circumcision is strongly associated with lower detection of any HPV and HR-HPV in urine, even after adjusting for key demographic and behavioural variables. However, circumcision was not associated with self-reported previous STI diagnosis/es in this population.

The strengths of this study are that the initial Natsal-3 sample size is large, and probability sampling gives data representative of the British general population. In contrast, studies included in the meta-analysis of the association between HPV and genital warts and circumcision were generally convenience samples with relatively small sample sizes. In addition to using self-reports of STI diagnosis/es, which may be subject to reporting bias (despite using CASI to collect these data), Natsal-3 used biological markers of STI, which have greater reliability. However, as the population prevalence of some of the STIs considered was low (specifically HPV-6/11, C. trachomatis and M. genitalium), statistical power was too low to detect modest differences in prevalence. Thus, the observed strong association between circumcision and lower detection of Chlamydia should be interpreted with caution since the 95% CIs around this are wide. It is also necessary to consider the method of sample collection. Urine tests for C. trachomatis and M. genitalium are regarded as the ‘gold standard’ in men, but urine is considered a suboptimum specimen for detection of HPV. Hernandez et al assessed HPV prevalence at different sites and found that it was highest in the penile shaft (52% at this site) compared to just 10% in urine, suggesting that HPV prevalence may be underestimated in our study. Another study found no difference in prevalence of HR-HPV in urethral swabs when comparing swabs taken before and after circumcision. Although detection bias

Table 2. Variations in the reported diagnosis of, and detection of, current infection, of key STIs among sexually-experienced men aged 16–44 years in Britain’s third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

| Reported diagnosis of: | Circumcised men | Uncircumcised men |
|------------------------|-----------------|-------------------|
|                        | % (95% CI)      | % (95% CI)        | OR (95% CI) | AOR¹ (95% CI) |
| Denom. (unw, wt)²      | 561, 627        | 2969, 2980        |
| Any STI ³              | 13.7% (10.8–17.2) | 13.9% (12.4–15.5) | 0.98 (0.73–1.32) | 1.05 (0.75–1.48) |
| Chlamydia infection    | 6.5% (4.8–8.8)  | 6.2% (5.3–7.2)    | 1.06 (0.73–1.52) | 1.23 (0.81–1.86) |
| Genital warts          | 3.5% (2.2–5.6)  | 3.9% (3.1–4.9)    | 0.88 (0.51–1.51) | 1.05 (0.60–1.86) |

| Current infection with: | Circumcised men | Uncircumcised men |
|-------------------------|-----------------|-------------------|
| Denom. (unw, wt)²       | 284, 403        | 1566, 1821        |
| HPV (any)               | 6.4% (4.0–10.2) | 18.6% (16.1–21.3) | 0.30 (0.18–0.51) | 0.26 (0.13–0.50) |
| HR-HPV ⁵                | 2.3% (1.0–4.9)  | 9.8% (7.8–12.2)   | 0.21 (0.09–0.49) | 0.14 (0.05–0.40) |
| Possible HR-HPV ⁶       | 0.6% (0.2–2.0)  | 2.4% (1.6–3.7)    | 0.25 (0.07–0.86) | 0.24 (0.06–0.94) |
| HPV-6/11                | 0.7% (0.2–2.5)  | 1.5% (0.8–2.7)    | 0.48 (0.11–2.00) | 0.58 (0.16–2.10) |
| Chlamydia trachomatis   | 0.1% (0.0–0.7)  | 1.3% (0.9–1.9)    | 0.08 (0.01–0.59) | 0.09 (0.01–0.77) |
| Mycoplasma genitalium   | 1.9% (0.7–5.1)  | 1.0% (0.6–1.7)    | 1.90 (0.62–5.87) | 0.61 (0.18–2.09) |

1 ORs adjusted for age, ethnicity, same sex experience and number of partners in lifetime (for diagnosis outcomes) or number of partners without a condom in the past year (for biological outcomes)
2 Unweighted, weighted denominators: all 16–44 year old men reporting at least one lifetime partner by the time of their interview for Natsal-3
3 Defined as chlamydia, gonorrhoea, genital warts, syphilis, trichomonas, herpes, NSU/NGU, epididymo-orchitis, public lice/crabs or hepatitis
4 Unweighted, weighted denominators: 16–44 year old men with one or more lifetime partner who provided a urine sample
5 Positive for type(s) 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68
6 Positive for type(s) 26, 53, 66, 70, 73 and/or 82

doi:10.1371/journal.pone.0130396.t002
remains a possible explanation for our findings if the presence of the foreskin means that urine may collect HPV coming from other sites (e.g. the glans/corona,[18,20,21] where prevalence is higher), in addition to the urethra. However, a systematic review and meta-analysis, which included data collected from a variety of anatomical sites, found results similar to our study and a stronger effect of circumcision at sites more proximal to the foreskin (urethra and glans/corona)[8] suggesting that the results presented here may not solely be due to differential detection.

The lack of association between male circumcision and self-reported previous STI diagnoses is in keeping with Natsal-2 findings,[22] and the meta-analysis of the association between circumcision and HPV,[8] which reported significantly lower odds of any HPV type (at any anatomical site) in circumcised men compared to uncircumcised men but no association with genital warts. Our data suggest an association between circumcision and lower odds of detection of C. trachomatis, consistent with some,[10] but not all other studies.[9] However, we did not find an association with reported diagnosis of Chlamydia. We are unable to compare our findings for HPV-6/11 or M. genitalium to the findings of other studies due to insufficient statistical power.

Data from a large national probability survey have shown that male circumcision is associated with lower odds of detecting oncogenic HPV types. Reduced prevalence of oncogenic HPV types among men may result in reduced transmission to sexual partners, with the consequent effect of reduced risk of cervical cancer. Castellague et al. observed that monogamous women whose partners had reported six or more sexual partners and who were circumcised were at lower risk of cervical cancer than monogamous women whose partners were uncircumcised.[23] Currently the World Health Organisation advocates male circumcision for HIV prevention;[24] reduction in HPV acquisition would add to the overall health benefit resulting from the scale-up of male circumcision in countries with high prevalence of HIV. In such settings this reduction could be important due to the higher incidence of cervical cancer, particularly among HIV positive women, as well as other HPV related cancers in both men and women than in higher income countries,[25] and the low or absent HPV vaccination coverage. This present study shows that male circumcision is associated with lower odds of detection of HR-HPV types, meaning it may convey a long-term public health benefit. Future research should be directed towards determining whether male circumcision might contribute to reducing rates of cervical, penile, anal and oral cancers.

Acknowledgments

Natsal-3 is a collaboration between University College London (London, UK), the London School of Hygiene and Tropical Medicine (London, UK), NatCen Social Research, Public Health England (formerly the Health Protection Agency), and the University of Manchester (Manchester, UK). Natsal-3 was supported by grants to AMJ from the Medical Research Council (www.mrc.ac.uk; G0701757) and the Wellcome Trust (www.wellcome.ac.uk; 084840), with contributions from the Economic and Social Research Council and Department of Health. NF is supported by a National Institute for Health Research Academic Clinical Lectureship (www.nihr.ac.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the study participants; the team of interviewers from NatCen Social Research; and operations and computing staff from NatCen Social Research; staff from the Department of HIV and Sexually Transmitted Infections, Public Health England for data linkage, anonymisation, and data entry; and laboratory staff from the Virus Reference Department and the Sexually Transmitted Bacteria Reference Unit, Public Health England for their contributions to development of protocols and testing.
Author Contributions
Conceived and designed the experiments: SB KP. Performed the experiments: SB KP. Analyzed the data: VH CT CHM. Wrote the paper: VH CT RFM SB NF PS KW KP AMJ CHM. Initial applicants for Natsal-3, wrote the study protocol and obtained funding: PS KW AMJ CHM. Designed the Natsal-3 questionnaire, applied for ethics approval, and undertook piloting of the questionnaire: CT NF PS KW AMJ CHM. Managed data: CT CHM. All authors interpreted data: VH CT RFM SB NF PS KW KP AMJ CHM.

References
1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657–666. PMID:17321311
2. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298. PMID:16231970
3. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643–656. PMID:17321310
4. Weiss HA, Thomas SL, Munabi SK, Hayes RJ (2006) Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 82: 101–109; discussion 110. PMID:16581731
5. Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, et al. (2013) Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 382: 1795–1806. doi:10.1016/S0140-6736(13)61947-9 PMID: 24286785
6. Cancer IAFRo (2009) A review of human carcinogens. Part B: Biological agents / IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Lyon, France.
7. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. (2009) Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus types (6, 11, 16, and 18) vaccine. J Infect Dis 199: 805–814. doi: 10.1086/597071 PMID: 19199546
8. Larke N, Thomas SL, Dos Santos Silva I, Weiss HA (2011) Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis 204: 1375–1390. doi: 10.1093/infdis/jir523 PMID: 21965090
9. Mehta SD, Moses S, Agot K, Parker C, Ndinya-Achola JO, Maclean I, et al. (2009) Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J Infect Dis 200: 370–378. doi: 10.1086/600074 PMID: 19545209
10. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B (2009) Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex Transm Infect 85: 116–120. doi: 10.1136/sti.2008.032334 PMID: 19074928
11. Erens B, Phelps A, Clifton S, Mercer CH, Tanton C, Hussey D, et al. Methodology of the third British National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Sex Transm Infect. 2014; 90: 84–89. doi: 10.1136/sextrans-2013-051359 PMID: 24277881
12. Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, et al. (2013) Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 382: 1781–1794. doi: 10.1016/S0140-6736(13)62035-8 PMID: 24286784
13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. (2009) A review of human carcinogens—Part B: biological agents. Lancet Oncol 10: 321–322. PMID: 19350508
14. Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscomet L, Parry JV, et al. (2011) Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 83: 1744–1751. doi: 10.1002/jmv.21837 PMID: 21837790
15. Jensen JS, Bjornelius E, Dohn B, Lidbrink P (2004) Use of TaqMan 5′ nuclelease real-time PCR for quantitative detection of Mycoplasma genitalium DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. J Clin Microbiol 42: 683–682. PMID: 14766837
16. Hardick J, Giles J, Hardick A, Hsieh YH, Quinn T, Gaydos C (2006) Performance of the gen-probe transcription-mediated [corrected] amplification research assay compared to that of a multitarget real-time PCR for Mycoplasma genitalium detection. J Clin Microbiol 44: 1236–1240. PMID: 16597844

17. Field N, Tanton C, Mercer CH, Nicholson S, Soldan K, Beddows S, et al. (2012) Testing for sexually transmitted infections in a population-based sexual health survey: development of an acceptable ethical approach. Journal of Medical Ethics 38: 380–382. doi: 10.1136/medethics-2011-100068 PMID: 22252417

18. Hernandez BY, Wilkens LR, Zhu X, McDuffie K, Thompson P, Shvestsov YB, et al. (2008) Circumcision and human papillomavirus infection in men: a site-specific comparison. J Infect Dis 197: 787–794. doi: 10.1086/528379 PMID: 18284369

19. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. (2009) Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 199: 14–19. doi: 10.1086/595566 PMID: 19086814

20. Nielson CM, Schiaffino MK, Dunne EF, Salemi JL, Giuliano AR (2009) Associations between male anogenital human papillomavirus infection and circumcision by anatomic site sampled and lifetime number of female sex partners. J Infect Dis 199: 7–13. doi: 10.1086/595567 PMID: 19086813

21. Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee SK, Meyer C, et al. (2004) Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 189: 677–685. PMID: 14767822

22. Dave SS, Johnson AM, Fenton KA, Mercer CH, Erens B, Wells K (2003) Male circumcision in Britain: findings from a national probability sample survey. Sex Transm Infect 79: 499–500. PMID: 14663134

23. Castellsagüé X, Bosch FX, Muñoz N, Meijer CJ, Shah KV, de Sanjose S, et al. (2002) Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346: 1105–1112. PMID: 11948269

24. WHO/UNAIDS (2013) Male circumcision for HIV prevention. Geneva: WHO.

25. Cancer IARo (2012) Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon: International Agency for Research on Cancer.